Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Nov 5, 2026
Reporting period
Not applicable
Filed with the SEC
Nov 9, 2026
CEOOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001628280-26-072360
Filed / recorded
Nov 9, 2026, 10:44 PM UTC
Added to OQRO
Nov 9, 2026, 10:50 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
BECTON DICKINSON & CO
Issuer CIK
10795
Ticker
BDX
Reporting person
Thomas E Jr Polen
Relationship
Director, Officer
Officer title
Chairman, CEO and President
Security
Stock Appreciation Rights
Table
Derivative (Table II)
Transaction date
Nov 5, 2026
Transaction code
M
Shares / units
20,239
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
20,239
Ownership form
Direct
Amendment
No
Footnotes from the filing
Award terms reflect the adjustments made in connection with the embecta spinoff and the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.
The stock appreciation rights vest in four annual installments beginning November 26, 2019.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.